Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of glycopyrronium bromide + neostigmine methylsulfate injection for reversal of residual non-depolarizing neuromuscular block
CTR20242429Phase 3Completed
- Sponsor
- Shanghai Pharma Dongying
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neostigmine + glycopyrrolate in neuromuscular block (NMB), sponsored by Shanghai Pharma Dongying. Started Jul 2024; status: completed.
02
Drugs
neostigmine + glycopyrrolate
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20242429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242429.